Stock Scorer

Legend Biotech Corp (LEGN)

Legend Biotech Corp reported revenue of 973.5M USD for the quarter ending 31 December 2025, up 94.3% from 501.1M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q4 '25 · ending 31 December 2025 973.5M +94.3%
Gross Profit Q4 '25 · ending 31 December 2025 854.1M +97.8%
Operating Income Q4 '25 · ending 31 December 2025 -19.6M —
Net Income Q4 '25 · ending 31 December 2025 -30.8M -217.1%
Cost of Revenue Q4 '25 · ending 31 December 2025 119.5M +72.1%
Operating Cash Flow Q4 '25 · ending 31 December 2025 -12.2M —
Free Cash Flow Q4 '25 · ending 31 December 2025 -24.6M —
Shares Outstanding Q3 '25 · ending 30 September 2025 369.3M +1.1%
EPS Q4 '25 · ending 31 December 2025 -0.81 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 1B-136.5M-296.8M-128.8M
20242024-12-31 627.3M-309.5M-177M-158.1M
20232023-12-31 285.1M-528.1M-518.3M-413.4M
20222022-12-31 50.3M—-446.3M-222.2M
20212021-12-31 68.8M—-403.6M-240.7M
20202020-12-31 75M—-266.4M-249.3M
20192019-12-31 60M—-101.6M-109.8M
20182018-12-31 49.1M—-2.8M286.7M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q4 '252025-12-31973.5M
Q3 '252025-09-3010.5M
Q2 '252025-06-3035.3M
Q1 '252025-03-319.4M
Q4 '242024-12-31501.1M
Q3 '242024-09-3017.4M
Q2 '242024-06-3093.3M
Q1 '242024-03-3115.5M
Q4 '232023-12-3179.4M
Q3 '232023-09-3096M
Q2 '232023-06-3073.3M
Q1 '232023-03-3136.3M
Q3 '222022-09-3027.4M

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q4 '252025-12-31854.1M
Q3 '252025-09-30-102.8M
Q2 '252025-06-30-59.5M
Q1 '252025-03-31-60.1M
Q4 '242024-12-31431.7M
Q3 '242024-09-30-35.1M
Q2 '242024-06-3047.9M
Q1 '242024-03-31-33.6M
Q4 '232023-12-3147M
Q3 '232023-09-3052.5M
Q2 '232023-06-3040.7M
Q1 '232023-03-31723K
Q3 '222022-09-301.9M

Operating Income Quarterly

PeriodEndingOperating Income
Q4 '252025-12-31-19.6M
Q3 '252025-09-30-43.5M
Q4 '242024-12-31-79.3M
Q3 '242024-09-30-70.4M

Net Income Quarterly

PeriodEndingNet Income
Q4 '252025-12-31-30.8M
Q3 '252025-09-30-39.7M
Q2 '252025-06-30-125.4M
Q1 '252025-03-31-100.9M
Q4 '242024-12-3126.3M
Q3 '242024-09-30-125.3M
Q2 '242024-06-30-18.2M
Q1 '242024-03-31-59.8M
Q4 '232023-12-31-144.9M
Q3 '232023-09-30-62.2M
Q2 '232023-06-30-199.1M
Q1 '232023-03-31-112.1M
Q4 '222022-12-31-135.9M
Q3 '222022-09-30-85M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q4 '252025-12-31119.5M
Q3 '252025-09-30113.3M
Q2 '252025-06-3094.9M
Q1 '252025-03-3169.5M
Q4 '242024-12-3169.4M
Q3 '242024-09-3052.5M
Q2 '242024-06-3045.4M
Q1 '242024-03-3149.1M
Q4 '232023-12-3132.4M
Q3 '232023-09-3043.5M
Q2 '232023-06-3032.7M
Q1 '232023-03-3135.6M
Q4 '222022-12-3123M
Q3 '222022-09-3025.5M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q4 '252025-12-31-12.2M
Q3 '252025-09-3028.8M
Q2 '252025-06-30-13M
Q1 '252025-03-31-103.8M
Q4 '242024-12-31-82M
Q3 '242024-09-30-75.8M
Q2 '242024-06-30-1.7M
Q1 '242024-03-3115.5M
Q4 '232023-12-31-95.7M
Q3 '232023-09-30-60.8M
Q2 '232023-06-30-97.6M
Q1 '232023-03-31-139.2M
Q4 '222022-12-31-49.7M
Q3 '222022-09-30-72.1M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-31-24.6M
Q3 '252025-09-3023.8M
Q2 '252025-06-30-22.3M
Q1 '252025-03-31-105.8M
Q4 '242024-12-31-84.4M
Q3 '242024-09-30-77.9M
Q2 '242024-06-30-5.1M
Q1 '242024-03-319.3M
Q4 '232023-12-31-100M
Q3 '232023-09-30-66.2M
Q2 '232023-06-30-103.7M
Q1 '232023-03-31-143.5M
Q4 '222022-12-31-56.3M
Q3 '222022-09-30-74.7M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q3 '252025-09-30369.3M
Q2 '252025-06-30368.3M
Q1 '252025-03-31367.5M
Q3 '242024-09-30366.6M
Q2 '242024-06-30365.2M
Q1 '242024-03-31364M
Q1 '232023-03-31330.5M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q4 '252025-12-31-0.81
Q3 '252025-09-30-0.65
Q2 '252025-06-30-0.88
Q1 '252025-03-31-0.59
Q4 '242024-12-31-0.48
Q3 '242024-09-30-0.95
Q2 '242024-06-30-0.77
Q1 '242024-03-31-1.29
Q4 '232023-12-31-1.47